Reuters logo
BRIEF-Novo Nordisk diabetes drug Victoza reduces risk of heart attacks
August 28, 2017 / 12:10 PM / 3 months ago

BRIEF-Novo Nordisk diabetes drug Victoza reduces risk of heart attacks

Aug 28 (Reuters) - NOVO NORDISK

* DIABETES DRUG VICTOZA REDUCES THE RISK OF MAJOR CARDIOVASCULAR EVENTS IN PEOPLE WITH TYPE 2 DIABETES WITH OR WITHOUT PRIOR EVENTS

* A NEW ANALYSIS OF THE LEADER TRIAL SHOWS THAT VICTOZA REDUCED THE RISK OF MAJOR CARDIOVASCULAR (CV) EVENTS IN PEOPLE WITH TYPE 2 DIABETES AT HIGH CV RISK, IRRESPECTIVE OF THEIR HISTORY OF HAVING A HEART ATTACK AND/OR STROKE OR NOT HAVING ANY OF THESE EVENTS, WHEN COMPARED TO PLACEBO

* THE POST-HOC ANALYSIS WAS PRESENTED ON MONDAY AT THE EUROPEAN SOCIETY OF CARDIOLOGY (ESC) ANNUAL CONGRESS IN BARCELONA, SPAIN.

* VICTOZA REDUCED THE RISK OF MAJOR CV EVENTS (NON-FATAL HEART ATTACK, NON-FATAL STROKE AND CV DEATH) BY 16 PERCENT IN PEOPLE WHO HAD ALREADY EXPERIENCED A HEART ATTACK AND/OR STROKE WHEN THE TRIAL STARTED

* A NON-SIGNIFICANT 11 PERCENT RISK REDUCTION WAS ACHIEVED WITH VICTOZA TREATMENT IN PEOPLE WHO HAD NOT EXPERIENCED A PRIOR HEART ATTACK AND/OR STROKE. SOURCE TEXT FOR EIKON: FURTHER COMPANY COVERAGE: (Copenhagen newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below